The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 4, 2014, Pages 269-283

  Kawalec, Paweł ^a   Mikrut, Alicja ^a   Łopuch, Sylwia ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Meta analysis; Safety; Sodium glucose cotransporter 2 inhibitor; Systematic review

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; GOSOGLIPTIN; LINAGLIPTIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; VILDAGLIPTIN; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; IMMUNOLOGIC FACTOR; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ABDOMINAL PAIN; ARTHRALGIA; BACKACHE; BODY MASS; BRONCHITIS; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); COUGHING; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; REPRODUCTIVE TRACT INFECTIONS; RISK; URINARY TRACT INFECTIONS;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIARRHEA; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; MEMBRANE TRANSPORT MODULATORS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTIVE TRACT INFECTIONS; RISK; SODIUM-GLUCOSE TRANSPORTER 2; URINARY TRACT INFECTIONS;

EID: 84897952259     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2494     Document Type: Review

References (39)

1. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2009; 32(1): 193-203. doi:10.2337/dc08-9025.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6): 540-559.
3. Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10(8): 638-645.
4. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012; 14(9): 810-820. doi:10.1111/j.1463-1326.2012.01606.x.
5. Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab 2013 May 13. doi: 10.1111/dom.12128
6. Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev 2013 Mar 5. doi: 10.1002/dmrr.2403
7. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Cochrane Collaboration and John Wiley, 2011. Available from: www.cochrane-handbook.org
8. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62(10): 1006-1012.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1): 1-12.
10. Yang W, Guan Y, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes 2012; 4(3): 227-237. doi:10.1111/j.1753-0407.2012.00213.x.
11. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010; 27(12): 1409-1419. doi:10.1111/j.1464-5491.2010.03131.x.
12. Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5mg twice daily versus 5mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin 2012; 28(9): 1465-1474.
13. DeFronzo RA, Hissa MN, Garber AJ, et al. Saxagliptin 014 study group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32(9): 1649-1655. doi:10.2337/dc08-1984.
14. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011; 94(2): 217-224. doi:10.1016/j.diabres.2011.07.035.
15. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375(9733): 2223-2233. doi:10.1016/S0140-6736(10)60407-2.
16. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97(3): 1020-1031. doi:10.1210/jc.2011-2260.
17. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin treated patients with type 2 diabetes. Diabetes Care 2004; 27(12): 2874-2880.
18. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30(4): 890-895.
19. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009; 41(5): 368-373. doi:10.1055/s-0028-1104604.
20. Pan C, Xing X, Han P, et al. Institution investigators. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14(8): 737-744. doi:10.1111/j.1463-1326.2012.01593.x.
21. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24(2): 537-550. doi:10.1185/030079908X260925.
22. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin study 020 group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29(12): 2638-2643.
23. Scott R, Loeys T, Davies MJ, Engel SS, for the Sitagliptin Study G. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes and Metab 2008; 10(10): 959-969. doi: 10.1111/j.1463-1326.2007.00839.x
24. Rosenstock J, Aggarwal N, Polidori D, et al. Study group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35(6): 1232-1238. doi:10.2337/dc11-1926.
25. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012; 28(7): 1167-1171. doi:10.1185/03007995.2012.689956.
26. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28(7): 1173-1178. doi:10.1185/03007995.2012.697053.
27. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, for the Alogliptin Study G. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63(1): 46-55. doi: 10.1111/j.1742-1241.2008.01933.x.
28. Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012; 14(10): 927-936. doi:10.1111/j.1463-1326.2012.01620.x.
29. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13(1): 65-74. doi:10.1111/j.1463-1326.2010.01326.x.
30. Rosenstock J, Lewin AJ, Norwood P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in type 2 diabetes. Diabet Med 2011; 28(4): 464-469. doi:10.1111/j.1464-5491.2010.03181.x.
31. Terra SG, Somayaji V, Schwartz S, et al. A dose-ranging study of the DPP-IV inhibitor PF-734200 added to metformin in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011; 119(7): 401-407. doi:10.1055/s-0031-1273737.
32. Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther 2012; 34(8): 1761-1771. doi:10.1016/j.clinthera.2012.06.027.
33. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013; 5(1): 6. doi:10.1186/1758-5996-5-6.
34. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; Jun 6. doi: 10.1002/phar.1303
35. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303(14): 1410-1418. doi:10.1001/jama.2010.405.
36. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012; 14: 1061-1072. doi:10.1111/j.1463-1326.2012.01610.x.
37. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34(2): 369-374. doi:10.2337/dc10-1771.
38. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2(5). doi:10.1136/bmjopen-2012-001007.
39. Raz I, Eldor R. Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms. Diabetes Metab Res Rev 2012; 28(4): 321-324. doi:10.1002/dmrr.2265.